Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isis Pharmaceuticals has started a Phase 1 trial to evaluate ISIS-PTP1BRx as a treatment for type 2 diabetes patients whose glucose is inadequately controlled by insulin or oral therapies.
Subscribe to our email newsletter
The antisense drug ISIS-PTP1BRx is intended to increase the body’s sensitivity to the natural hormone insulin, helping in better glucose control for patients suffering from type 2 diabetes.
Initially, the Phase 1 trial will treat diabetic patients who are inadequately controlled on insulin, helping them utilize insulin more efficiently; and patients who are beginning to fail oral therapies, extending the time they have before becoming dependent on insulin.
Isis Pharma Metabolic Disorders and Translational Medicine vice president Sanjay Bhanot said ISIS-PTP1BRx selectively reduces only the PTP-1B protein, a mechanism distinct from current insulin sensitizers, it is unlikely to have those side effects.